News Greenberg Traurig’s David J. Dykeman Speaks at ACI Summit on Life Sciences IP Due Diligence Nov 28, 2022 Posted by Greenberg Traurig, LLP
News EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia Nov 20, 2022
News EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies Nov 20, 2022
News Greenberg Traurig Intellectual Property & Technology Practice Continues Growth in Boston Nov 15, 2022 Posted by Greenberg Traurig, LLP
News Flare™ V6.1 released: New features and science enable rapid exploration and analysis of lead compounds and ligand series, and effective communication of project results Nov 15, 2022 Posted by Cresset
News New Flare™ Python Cookbook recipes enable research chemists to rapidly explore and compare ligands and focus on only relevant results Nov 15, 2022 Posted by Cresset
News ConcertAI Names Ronan Brown as its First Chief Operations Officer Nov 15, 2022 Posted by ConcertAI
News EVERSANA® Names Experienced Life Sciences Leader Sy Pretorius Chief Operating Officer & President, Outsourced Solutions to Propel Next-Generation Commercialization Services Worldwide Nov 14, 2022
News Greenberg Traurig’s Boston IP Group Congratulates 3 Clients on Winning 2022 BPLA ‘Invented Here!’ Awards Nov 11, 2022 Posted by Greenberg Traurig, LLP
